Skip to search formSkip to main contentSkip to account menu

IMC-18F1

Known as: IMC18F1 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IcrucumabMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with…
TPS151 Background: Ramucirumab is a fully human IgG1 monoclonal antibody (MAb) that targets the VEGFR-2, blocks the interaction… 
2008
2008
Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies
14630 Background: VEGFR-1 is expressed on both tumor vasculature and a wide range of human tumors. IMC-18F1 is a recombinant… 
2006
2006
Anti-Vascular Endothelial Growth Factor Receptor-1Antagonist Antibody as aTherapeutic Agent for Cancer
Purpose: Vascular endothelial growth factor receptor-1 (VEGFR-1) plays important roles in promotion of tumor growth by mediating… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)